MedPath

A prospective study comparing the pharmacokinetics, efficacy, and side effects of sunitinib in patients with advanced renal cell carcinoma

Not Applicable
Conditions
Renal cell carcinoma
Registration Number
JPRN-UMIN000014685
Lead Sponsor
Department of Urology, Osaka International Cancer Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with serious illness in kidney, liver, heart, or hematogenous function 2. Disqualified by a medical doctor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relationship between trough concentrations of sunitinib and side effects
Secondary Outcome Measures
NameTimeMethod
Relationship between trough concentrations of sunitinib and efficacy
© Copyright 2025. All Rights Reserved by MedPath